Literature DB >> 18752121

SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma.

Sheau-Fang Yang1, Yao-Tsung Yeh, Shen-Nien Wang, Sz-Chi Hung, Wan-Tzu Chen, Chu-Ho Huang, Chee-Yin Chai.   

Abstract

AIMS: Alteration of the suppressor of cytokine signalling-3 (SOCS-3) has been observed in certain human cancers. However, the clinical role of this short-lived protein in hepatocellular carcinoma (HCC) is not well established. Therefore, we aimed to explore the potential role of SOCS-3 proteins in HCC.
METHODS: Paraffin embedded sections from 87 HCC patients were included in this study. The expression patterns of SOCS-3 proteins were analysed using immunohistochemistry and the results were correlated with clinicopathological characteristics and overall survival of the HCC patients.
RESULTS: The SOCS-3 expression of HCC lesions and the adjacent non-tumourous liver tissues was significantly correlated (p = 0.035), while the SOCS-3 expression in HCC lesions was significantly and positively correlated with vascular invasion and histological grading (p = 0.034 and 0.032, respectively). The Kaplan-Meier survival curve showed that the HCC patients with high SOCS-3 expression were associated with a poor overall survival rate in the HCC subgroup with positive vascular invasion (p = 0.014). Furthermore, a multivariate Cox regression model showed that SOCS-3 expression was also a significant determinant of the overall survival for HCC (p = 0.006).
CONCLUSIONS: Our results indicate that altered SOCS-3 expression is associated with the overall survival in a subset of HCC patients with positive vascular invasion. Constitutive and altered SOCS-3 expression may have potential roles in a subset of HCC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752121     DOI: 10.1080/00313020802320432

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  10 in total

1.  Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma.

Authors:  Wen-Yong Wu; Jun Li; Zheng-Sheng Wu; Chang-LE Zhang; Xiang-Ling Meng; Peter E Lobie
Journal:  Exp Ther Med       Date:  2011-04-11       Impact factor: 2.447

2.  Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma.

Authors:  Mingzhen Ying; Dawei Li; Linjun Yang; Mei Wang; Ning Wang; Ying Chen; Miaoxia He; Yajie Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-14       Impact factor: 4.553

3.  Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue--influence of a modulated host stroma on the prognosis of HCC.

Authors:  Frank Simon; Maximilian Bockhorn; Christian Praha; Hideo A Baba; Christoph E Broelsch; Andrea Frilling; Frank Weber
Journal:  Langenbecks Arch Surg       Date:  2010-02-18       Impact factor: 3.445

Review 4.  Suppressors of Cytokine Signaling and Hepatocellular Carcinoma.

Authors:  Ryota Masuzaki; Tatsuo Kanda; Reina Sasaki; Naoki Matsumoto; Kazushige Nirei; Masahiro Ogawa; Seth J Karp; Mitsuhiko Moriyama; Hirofumi Kogure
Journal:  Cancers (Basel)       Date:  2022-05-22       Impact factor: 6.575

5.  Leptin inhibits hepatocellular carcinoma proliferation via p38-MAPK-dependent signalling.

Authors:  Kyle J Thompson; Kwan N Lau; Sarah Johnson; John B Martinie; David A Iannitti; Iain H McKillop; David Sindram
Journal:  HPB (Oxford)       Date:  2011-01-27       Impact factor: 3.647

6.  Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion.

Authors:  Carlos Rossa; Gunhild Sommer; Luis C Spolidorio; Steven A Rosenzweig; Dennis K Watson; Keith L Kirkwood
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

7.  Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation.

Authors:  Ji Hoon Kim; Bo Hwa Sohn; Hyun-Sung Lee; Sang-Bae Kim; Jeong Eun Yoo; Yun-Yong Park; Woojin Jeong; Sung Sook Lee; Eun Sung Park; Ahmed Kaseb; Baek Hui Kim; Wan Bae Kim; Jong Eun Yeon; Kwan Soo Byun; In-Sun Chu; Sung Soo Kim; Xin Wei Wang; Snorri S Thorgeirsson; John M Luk; Koo Jeong Kang; Jeonghoon Heo; Young Nyun Park; Ju-Seog Lee
Journal:  PLoS Med       Date:  2014-12-23       Impact factor: 11.069

8.  The prognostic role of BORIS and SOCS3 in human hepatocellular carcinoma.

Authors:  Rongce Zhao; Kefei Chen; Jing Zhou; Jingyang He; Jun Liu; Peng Guan; Bo Li; Yang Qin
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

9.  Genetic Deletion of mGlu3 Metabotropic Glutamate Receptors Amplifies Ischemic Brain Damage and Associated Neuroinflammation in Mice.

Authors:  Federica Mastroiacovo; Manuela Zinni; Giada Mascio; Valeria Bruno; Giuseppe Battaglia; Julien Pansiot; Tiziana Imbriglio; Jerome Mairesse; Olivier Baud; Ferdinando Nicoletti
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

10.  FXR induces SOCS3 and suppresses hepatocellular carcinoma.

Authors:  Fei Guo; Zhizhen Xu; Yan Zhang; Peng Jiang; Gang Huang; Shan Chen; Xilin Lyu; Ping Zheng; Xin Zhao; Yijun Zeng; Shuguang Wang; Fengtian He
Journal:  Oncotarget       Date:  2015-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.